The Imaging and Informatics in Retinopathy of Prematurity (i-ROP) Research Consortium includes the following: Michael F. Chiang, Susan Ostmo, Sang Jin Kim, Kemal Sonmez, and J. Peter Campbell (Oregon Health & Science University, Portland, OR); R. V. Paul Chan and Karyn Jonas (University of Illinois at Chicago, Chicago, IL); Jason Horowitz, Osode Coki, Cheryl-Ann Eccles, and Leora Sarna (Columbia University, New York, NY); Anton Orlin (Weill Cornell Medical College, New York, NY); Audina Berrocal and Catherin Negron (Bascom Palmer Eye Institute, Miami, FL); Kimberly Denser, Kristi Cumming, Tammy Osentoski, Tammy Check, and Mary Zajechowski (William Beaumont Hospital, Royal Oak, MI); Thomas Lee, Evan Kruger, and Kathryn McGovern (Children's Hospital Los Angeles, Los Angeles, CA); Charles Simmons, Raghu Murthy, and Sharon Galvis (Cedars Sinai Hospital, Los Angeles, CA); Jerome Rotter, Ida Chen, Xiaohui Li, Kent Taylor, and Kaye Roll (Los Angeles Biomedical Research Institute, Los Angeles, CA); Jayashree Kalpathy-Cramer (Massachusetts General Hospital, Boston, MA); Deniz Erdogmus and Stratis Ioannidis (Northeastern University, Boston, MA); Maria Ana Martinez-Castellanos, Samantha Salinas-Longoria, Rafael Romero, Andrea Arriola, Francisco Olguin-Manriquez, Miroslava Meraz-Gutierrez, Carlos M. Dulanto-Reinoso, and Cristina Montero-Mendoza (Asociacion para Evitar la Ceguera en Mexico, Mexico City, Mexico).
This project was supported by grants R01EY19474, K12EY027720, and P30EY10572 from the National Institutes of Health; by grants SCH-1622679, SCH-1622542, and SCH-1622536 from the National Science Foundation; and by unrestricted departmental funding and a Career Development Award from Research to Prevent Blindness (JPC).
Disclosure: V.M. Yildiz, None; P. Tian, None; I. Yildiz, None; J.M. Brown, None; J. Kalpathy-Cramer, None; J. Dy, None; S. Ioannidis, None; D. Erdogmus, None; S. Ostmo, None; S.J. Kim, None; R.V.P. Chan, Visunex Medical Systems Scientific Advisory Board (S), Genentech (C); J.P. Campbell, None; M.F. Chiang, Clarity Medical Systems Scientific Advisory Board (S), Novartis (C), and Inteleretina (I)